Last updated: February 19, 2026
This report analyzes key considerations for securing and enforcing biopharmaceutical patents in the Russian Federation. It details patentability requirements, enforceability mechanisms, and typical claim scope for this sector, based on Russian patent law and relevant guidelines.
What are the Core Patentability Requirements for Biopharmaceuticals in Russia?
Biopharmaceutical inventions in Russia must meet fundamental patentability criteria: novelty, inventive step, and industrial applicability.
Novelty
An invention is novel if it is not part of the prior art. Prior art includes any publicly available information worldwide before the filing date. For biopharmaceuticals, this encompasses scientific publications, existing patents, and public use or sale of similar products [1].
Inventive Step
An invention involves an inventive step if it is not obvious to a person skilled in the art. This requires demonstrating that the claimed invention would not have been readily apparent to a specialist based on existing knowledge. This often involves showing unexpected results or overcoming technical challenges [2].
Industrial Applicability
The invention must be capable of being made or used in industry. For biopharmaceuticals, this means the invention must have a practical application, such as a therapeutic use or a diagnostic method [3].
How Does Russia Handle Patenting of Biological Subject Matter?
Russian patent law addresses biological subject matter through specific provisions and interpretations.
Patentable Inventions
- Products: New pharmaceutical compositions, formulations, and specific active ingredients derived from biological sources are patentable [4]. This includes novel proteins, antibodies, and nucleic acids.
- Processes: Methods for producing biological materials, diagnostic methods involving biological markers, and methods of treatment using biopharmaceuticals are also patentable [3, 5].
- Discovery vs. Invention: Mere discovery of a new biological entity or its function is generally not patentable. However, if the discovery leads to a practical application (e.g., a new diagnostic kit or therapeutic use), it can form the basis of a patentable invention [1].
Non-Patentable Subject Matter
- Human Body and Methods of Treatment: The human body at various stages of its development, as well as methods for treatment, surgical, and diagnostic methods practiced directly on the human or animal body, are explicitly excluded from patentability [4].
- Exception: This exclusion does not apply to products, including substances or compositions, for use in any of these methods. This means a new drug substance or a new use of a known drug substance is patentable, even if its ultimate application is a medical treatment.
Deposit of Biological Material
For inventions involving microorganisms or where the invention cannot be described in a manner sufficiently clear and complete for a person skilled in the art to carry it out, a deposit of the biological material must be made with a recognized depositary institution according to the Budapest Treaty [6]. The Russian National Depositary for Microorganisms (RNDM) is an example.
What are the Key Considerations for Claim Scope in Biopharmaceutical Patents?
Claim scope in Russian biopharmaceutical patents is influenced by patentability requirements and legal interpretations.
Types of Claims
- Composition of Matter Claims: These claims cover the novel biological entity itself, such as a specific DNA sequence, protein, antibody, or a pharmaceutical formulation containing these [7].
- Method of Use Claims: These claims cover specific therapeutic or diagnostic uses of a known or novel biopharmaceutical [5]. This is particularly important for second medical use patents.
- Process Claims: These claims cover methods for producing the biopharmaceutical, such as a specific recombinant DNA technology or a purification process [3].
Breadth of Claims
- Support: Claims must be fully supported by the description. This means the specification must provide sufficient detail to enable a person skilled in the art to make and use the claimed invention [8]. For biopharmaceuticals, this often requires detailed characterization of the molecule, its function, and its therapeutic utility.
- Enabling Disclosure: A patent must enable the public to carry out the invention. For novel proteins or antibodies, this may necessitate providing sequences, methods of production, and demonstrated efficacy data [9].
- Markush Claims: These claims, which allow for generic representation of a variable substituent, are permissible but must be carefully drafted to ensure each alternative is adequately supported and novel [7].
- Polymorphs and Salts: Claims directed to specific crystalline forms (polymorphs), salts, or solvates of an active pharmaceutical ingredient are patentable if they demonstrate an unexpected technical effect or improved properties compared to known forms [2].
How are Biopharmaceutical Patents Enforced in Russia?
Enforcement of biopharmaceutical patents in Russia involves administrative and judicial proceedings.
Infringement
Patent infringement occurs when a third party makes, uses, offers for sale, sells, or imports a patented invention without the patent holder's consent [10].
Remedies for Infringement
- Injunctions: Courts can order an infringer to cease all infringing activities [11].
- Damages: Patent holders can seek monetary compensation for losses incurred due to infringement. This can include lost profits or a reasonable royalty [11].
- Seizure and Destruction: Infringing goods can be seized and destroyed [10].
Enforcement Procedures
- Pre-litigation: This typically involves sending a cease-and-desist letter to the alleged infringer.
- Court Proceedings: If pre-litigation measures fail, a lawsuit can be filed in the Arbitration Court.
- Expert Evidence: Technical expertise is often crucial in patent infringement cases, especially in the biopharmaceutical sector, to establish whether the accused product falls within the scope of the patent claims.
- Patent Invalidation: An alleged infringer can challenge the validity of a patent during an infringement proceeding or through a separate administrative action at the Chamber for Patent Disputes (part of Rospatent) [12]. Grounds for invalidation include lack of novelty, inventive step, or insufficient disclosure.
Role of the Chamber for Patent Disputes (Rospatent)
The Chamber for Patent Disputes handles pre-grant oppositions and post-grant invalidation proceedings. Decisions of the Chamber can be appealed in court [12].
Border Measures
Customs authorities can detain imported goods suspected of infringing patent rights, based on information provided by the patent holder [13].
What are the Specifics of Patent Term Extension (Supplementary Protection Certificates - SPCs) in Russia?
Russia has provisions for extending patent protection for pharmaceutical products.
Supplementary Protection Certificates (SPCs)
- Purpose: SPCs are intended to compensate for the time lost during the regulatory approval process. They extend the effective life of a patent for a specific medicinal product [14].
- Eligibility: An SPC can be granted for a patent covering a medicinal product that requires a marketing authorization before it can be placed on the market [14].
- Duration: The term of an SPC is calculated as the period between the patent filing date and the date of the first marketing authorization in Russia, minus five years, with a maximum extension of five years [14].
- Application: An application for an SPC must be filed within six months of the date of the first marketing authorization in Russia or within six months of the patent grant date, whichever is later [14].
Key Takeaways
- Biopharmaceutical patentability in Russia hinges on novelty, inventive step, and industrial applicability, with specific considerations for biological subject matter.
- Methods of treatment are not patentable, but products and compositions for use in treatment, as well as their specific uses, are.
- Claim scope must be adequately supported by the patent description, which requires detailed characterization and enabling disclosures.
- Enforcement involves administrative and judicial actions, with remedies including injunctions and damages.
- Supplementary Protection Certificates (SPCs) can extend patent protection for medicinal products to compensate for regulatory delays.
FAQs
-
Can a naturally occurring protein that has been isolated and purified be patented in Russia?
Yes, if the isolated and purified protein is novel, involves an inventive step, and has a new industrial application. The mere discovery of a naturally occurring protein is not patentable, but its isolation and characterization for a specific, non-obvious use may qualify.
-
Are diagnostic methods using genetic markers patentable in Russia?
Diagnostic methods practiced directly on the human or animal body are not patentable. However, a method for diagnosing a disease using a genetic marker, which involves analyzing a biological sample ex vivo and providing information for medical decision-making, can be patentable if it meets novelty, inventive step, and industrial applicability requirements.
-
What is the typical timeframe for obtaining a patent for a biopharmaceutical in Russia?
The standard examination process for a patent application in Russia takes approximately 18-24 months from the filing date to the first office action, and potentially longer for final grant, depending on the complexity and responsiveness to office actions. This can be expedited through specific requests.
-
Does Russia offer patent linkage or data exclusivity separate from SPCs for biopharmaceuticals?
Russia does not have a formal "patent linkage" system in the U.S. sense. However, regulatory data exclusivity is provided under Article 13.2 of the Federal Law "On Circulation of Medicines for Medical Use," which grants a period of exclusivity for the efficacy and safety data submitted for registration of a new medicinal product. This is distinct from SPCs, which extend patent life.
-
How does the Russian patent office assess inventive step for biopharmaceuticals, particularly regarding unexpected results?
The Russian patent office (Rospatent) assesses inventive step by considering whether the claimed invention would have been obvious to a person skilled in the art based on the prior art. For biopharmaceuticals, demonstrating unexpected technical results, such as significantly improved efficacy, reduced side effects, or overcoming a long-standing technical prejudice, is a strong indicator of inventive step. This often requires comparative data and experimental evidence presented in the patent application.
Citations
[1] World Intellectual Property Organization. (2022). WIPO Guide to Intellectual Property]. Retrieved from https://www.wipo.int/guide-ip/en/ (General IP principles applicable to Russian law)
[2] Rospatent. (2020). Administrative Regulations for the Performance of the Federal Service for Intellectual Property of State Functions on the Provision of Services in the Field of Intellectual Property. (Specifics on patent examination)
[3] Federal Law No. 141-FZ of July 23, 2013 "On Amendments to the Civil Code of the Russian Federation Parts One, Two and Four". (Provisions on patentability and industrial applicability)
[4] Civil Code of the Russian Federation, Part Four. (Article 1350 on patentability)
[5] Eurasian Patent Convention. (2000). Eurasian Patent Convention. (While not Russian law, it influences regional patenting and principles)
[6] Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. (1977).
[7] Thorne, J. (2018). Patentability of Biologics in Russia. Biotechnology Law Report, 37(5), 473-481.
[8] Rospatent. (2018). Guidelines for Examination of Applications for Inventions. (Specific guidelines for examination)
[9] International Bureau of WIPO. (2005). PCT Applicant's Guide: International Phase. (General principles of disclosure applicable to PCT national phases)
[10] Civil Code of the Russian Federation, Part Four. (Article 1358 on patent infringement)
[11] Federal Law No. 14-FZ of January 24, 2007 "On Patent Rights". (Provisions on enforcement and remedies)
[12] Rospatent. (n.d.). Chamber for Patent Disputes. Retrieved from https://rupto.ru/en/ (Information on administrative procedures)
[13] Federal Law No. 311-FZ of November 27, 2010 "On Customs Regulation in the Russian Federation". (Provisions on border measures)
[14] Government Decree of the Russian Federation No. 1993 of December 23, 2015 "On the Extension of the Term of Effect of Patents for Medicinal Products". (Regulations on SPCs)
